SHANGHAI, Nov. 15, 2019 -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it
capability and technology platform, today announced that it has been awarded the 2017 frost & sullivan global integrated drug r&d services competitive strategy innovation & leadership award. read more 2017/07/31 wuxi’s pharmaceutical development services division merges with sta shanghai, july 31, ...
i. The Company provides a full range of laboratory testing services to our customers, including DMPK (drug metabolism and pharmacokinetics), toxicology, and bioanalysis for drug development testing as well as medical device testing. We leveraged our integrated WuXi AppTec Investigational New Drug (IND...
Senior Research Scientist I Shanghai Good job as a first job, but don't stay too long. As a new graduate you will learn a lot from the company within half a year if you are lucky enough to pass the probation. For sure, you need have any price to haggle at this time. Payment is...
What kind of company is WuXi AppTec (Suzhou) Co., Ltd.? Suzhou WuXi AppTec New Drug Development Co., Ltd., established on 2006-10-08, Business scope includes licensed projects:Inspection and testing service;Import... What is WuXi AppTec (Suzhou) Co., Ltd.'s official website?
WuXi STA's platform will enable BioNova to accelerate new drug innovation as well as localization for licensed-in products towards commercialization. "We are delighted to establish this strategic collaboration with WuXi STA. As a leading CDMO company, WuXi STA is well known for its world-class ...
SHANGHAI, March 27, 2019 – STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its new drug product manufacturing facility in Shanghai Pilot Free Trade Zone has passed its first GMP inspection by the European Medica
peptide CRDMO, and cell and gene therapy services. Wuxi AppTec’s CRDMO services consists new drug development, material requirements, commercialization, and covers synthetic molecular modalities. The company operates in Asia, Europe, and North America. Wuxi AppTec is headquartered in Shanghai, China...
· Q1-Q3 revenue of clinical CRO & SMO grew 3.4% year-over-year to RMB1.36 billion. Among which, SMO revenue grew 16.0% year-over-year, maintaining industry leading position in China. In the first three quarters, SMO supported 50 new drug approvals for customers, and Clinical CRO enabled...
it is involved in pharmaceutical research and development; pharmacology, toxicology, and safety evaluation research services; and new drug clinical development and on-site management services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of Chi...